ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.
1 .- 37 . (canceled)
38 . A pharmaceutical composition comprising about 0.01 mg/kg/day to about 25 mg/kg/day, of a compound of the Formula:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
39 . The pharmaceutical composition of claim 38 wherein the compound is
40 . The pharmaceutical composition of claim 38 wherein the composition comprises about 0.1 mg/kg/day to about 10 mg/kg/day of the compound.
41 . The pharmaceutical composition of claim 38 wherein the composition comprises about 0.2 mg/kg/day to about 5 mg/kg/day mg of the compound.
42 . The pharmaceutical composition of claim 38 wherein the composition is formulated for oral delivery.
43 . The pharmaceutical composition of claim 38 wherein the composition is in a capsule or tablet.